Table 4.
Significant HLA allele differences in patient subgroups (before Bonferroni's correction)
| Subgroups/HLA allele | Patients | Controls | p value |
|---|---|---|---|
| Anti-AchR antibodies (+) | |||
| B*50 | 7 (8.6) | 7 (2.8) | 0.023 |
| C*05 | 12 (14.8) | 17 (6.8) | 0.027 |
| EOMG | |||
| DRB1*14 | 10 (20.8) | 25 (10.0) | 0.033 |
| DQB1*02 | 21 (43.8) | 59 (23.6) | 0.004 |
| Very-late onset MG | |||
| B*50 | 3 (14.3) | 7 (2.8) | 0.034 |
| C*01 | 0 | 43 (17.2) | 0.031 |
| DQB1*03 | 9 (42.9) | 171 (68.4) | 0.017 |
| DQB1*06 | 12 (57.1) | 76 (30.4) | 0.012 |
| Ocular MG | |||
| C*05 | 4 (25.0) | 17 (6.8) | 0.028 |
| DRB1*01 | 4 (25.0) | 20 (8.0) | 0.044 |
| DRB1*11 | 11 (68.8) | 81 (32.4) | 0.003 |
| Thymic hyperplasia | |||
| A*01 | 9 (32.1) | 36 (14.4) | 0.016 |
| A*31 | 4 (14.3) | 10 (4.0) | 0.041 |
| B*08 | 7 (25.0) | 25 (10.0) | 0.018 |
| DRB1*14 | 8 (28.6) | 25 (10.0) | 0.004 |
| DQB1*03 | 12 (42.9) | 171 (68.4) | 0.007 |
| Hashimoto thyroiditis | |||
| B*39 | 2 (16.7) | 5 (2.0) | 0.036 |
| Graves' disease | |||
| C*05 | 3 (30.0) | 17 (6.8) | 0.033 |
| C*07 | 0 | 89 (35.6) | 0.017 |
| DQB1*03 | 3 (30.0) | 171 (68.4) | 0.017 |
Values are presented as numbers (%) unless otherwise stated. HLA, human leucocyte antigen; MG, myasthenia gravis.